Dev Crease joined Keltie in 2004 just after he qualified as a UK and European patent attorney. Over past 16 years he has developed a thriving practice in the life sciences, chemical and medical technologies team based around advising rapid growth companies achieve value in their IP positions.
I was based in a very academic lab in an Institute in Cambridge, UK. I really enjoyed the molecular biology and being part of a lab but working at the bench in the late 90s was a very artisanal experience. Experiments would take several days to plan and then might take many weeks to complete manually. Automation was still in its infancy and I probably spent less time thinking about the science than I really wanted to. I was working in a very competitive area of developmental biology too and yet I was interested in so many different aspects of science and technology.
At that time the biotech boom was only just starting and it was unusual for academics in the UK to leave academia to join one of the very few start-ups. I think if it was a couple of years later I probably would have moved into the start-up biotech space as that has been where I have worked, albeit from the perspective of a patent attorney, for the majority of my career.
I was lucky enough to train as a patent attorney in an old traditional firm which had a range of clients from the very large pharmaceutical companies through to a few smaller start-ups. There was always a tension, though, between pleasing the big companies and dealing with less experienced early stage start-ups. That firm took the view that the relationships with big pharma companies were significantly more important than with the smaller emerging companies. I felt that even big pharma started from small beginnings, and it's in those early stages that meaningful longstanding client-adviser relationships can be built. I think I do take my work quite personally and I love to see clients grow and prosper and develop over time. I have been lucky enough to witness the full cycle of growth and exit for some fantastic companies over the course of my career.
I really enjoy establishing the early stage foundations for the IP in a company. If you get it right from the beginning, both by educating the founders of the company and ensuring that they can confidently survive multiple rounds of due diligence then I think I've done my job. I always say to my clients that patents are part of a wide range of different overlapping rights that can protect both their investment in creativity as well as ensure that they gain maximum value from their intellectual input. From time to time I am brought in to sort out the IP situation in companies that have not benefitted from coherent advice in the early days. It can be dismaying to see in these situations how value has been lost and resource has to be spent on recouping a position in a quickly evolving market. Setting things up so that companies can thrive is key. At the earliest stage, most start-ups have very little in the way of fixed assets and are entirely dependent upon their human resources and their intellectual property position to contribute to meaningful valuation.
I certainly hope so, the range of technologies that are being developed now and the funding opportunities within Europe, Asia and North America for early stage emerging technologies is amazing. I have been privileged to witness the growth of regenerative medicine, synthetic biology, machine learning as applied to biology, and the new wave of precision medicine. A whole range of new renewable technologies based on synthetic biology, artificial intelligence and novel organic materials also offer enormous promise to tackle the challenges of climate change that we face now and in the future. I think that being a part of this industry is never going to be boring and I really look forward to continuing to learn about new solutions to problems that can help make the world a better and safer place to live.
20.02.2024Charting a new course: Is the UK one of the most patent-holder-friendly jurisdictions for AI?
The UK High Court has recently reshaped the landscape of AI patentability, deeming neural networks not to be excluded under the UK's computer program exclusion. In a groundbreaking ruling, the court's decision challenges conventional boundaries. It raises the question: Has the UK become the most patent-holder-friendly jurisdiction in Europe for AI?
05.12.2023Keltie turns 35: A journey of innovation and excellence with Rosemary Cardas
Having started her career in 1986 with an established trade mark and patent attorney firm, Rosemary joined David Keltie in founding David Keltie Associates, (now Keltie) in 1988. She became partner in 1994. She is a Chartered Trade Mark Attorney and a Member of the Chartered Institute of Trade Mark Attorneys